Ethereum dropped below the $2,000 mark, hitting an intraday low of $1,955 due to renewed selling pressure and negative sentiment. BitMine slowed its Ethereum purchases after surpassing its target supply share, holding $9 billion in unrealized losses. Institutional investors continue withdrawing from Ethereum ETFs in the U.S. for a third week, signaling hesitation. Key support at $1,909 is critical; a break below could lead to further declines toward $1,741 or lower.
Fulcrum Therapeutics' stock dropped nearly 50% in after-hours trading after the company announced it is discontinuing its lead experimental drug, pociredir, for sickle cell disease. The decision follows FDA concerns about cancer risks linked to the d...
Inventiva, a clinical-stage biopharmaceutical company, has temporarily suspended trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 CEST. This suspension is at the company's request and precedes a planned financing operat...
Inventiva, a clinical-stage biopharmaceutical company, has temporarily halted trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 a.m. CEST. This pause is at the company's request and precedes a proposed financing transact...
The FDA has accepted Roche's New Drug Application for giredestrant, an oral selective estrogen receptor degrader (SERD), as an adjuvant treatment for early-stage ER-positive, HER2-negative breast cancer. The approval decision is expected by November ...
dsm-firmenich announced ongoing progress in its share repurchase program, buying back 184,000 shares between May 25-29, 2026, at an average price of €72.36 per share, totaling €13.3 million. This is part of a larger €540 million buyback initiated in ...
